Annexon, Inc. announced the appointment of biotech executive Bettina M. Cockroft, M.D., senior vice president and chief medical officer of Sangamo Therapeutics, Inc., to the company's board of directors. Dr. Cockroft joins the Annexon board of directors with nearly 20 years of experience in senior management roles in the biopharmaceutical industry and has worked across multiple therapeutic areas and led programs in several countries.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.695 USD | +2.29% | +3.84% | +4.30% |
Apr. 01 | JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating | MT |
Mar. 27 | Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.30% | 413M | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.44% | 29.48B | |
+57.35% | 25.43B | |
-18.06% | 11.49B | |
-44.02% | 11.3B | |
-15.61% | 11.1B | |
+4.42% | 8.75B | |
-8.42% | 7.99B |
- Stock Market
- Equities
- ANNX Stock
- News Annexon, Inc.
- Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to Its Board of Directors